Progressive liver fibrosis, induced by chronic viral and metabolic disorders, leads to more
than one million deaths annually via development of cirrhosis, although no antifibrotic …

Liver disease is a major global health-care problem, affecting an estimated 844 million
people worldwide. Despite this substantial burden, therapeutic options for liver disease …

Liver cirrhosis is a major cause of death worldwide and is characterized by extensive
fibrosis. There are currently no effective antifibrotic therapies available. To obtain a better …

Advanced liver disease presents a significant worldwide health and economic burden and
accounts for 3.5% of global mortality. When liver disease progresses to organ failure the …

Endothelial–mesenchymal transition (EndMT) is an important source of cancer-associated
fibroblasts (CAFs), which facilitates tumour progression. PDAC is characterised by abundant …

Background & Aims Cholangiocarcinoma (CCA) is a cancer of the hepatic bile ducts that is
rarely resectable and is associated with poor prognosis. Tumour necrosis factor-like weak …

Excessive alcohol consumption is a global healthcare problem with enormous social,
economic, and clinical consequences. While chronic, heavy alcohol consumption causes …

TWEAK (tumor necrosis factor-like weak inducer of apoptosis) is a member of the TNF
superfamily that controls a multitude of cellular events including proliferation, migration …

Macrophages are a heterogeneous population of innate immune cells and key cellular
components of the liver. Hepatic macrophages consist of embryologically-derived resident …

Background and Aims Acute liver damage causes hepatocyte stress and death, but in
chronic liver disease impaired hepatocyte regeneration and immune cell infiltration prevents …